{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T01:16:11Z","timestamp":1748049371393,"version":"3.40.4"},"reference-count":12,"publisher":"Japanese Society of Internal Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,5,1]]},"DOI":"10.2169\/internalmedicine.4270-24","type":"journal-article","created":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T22:10:57Z","timestamp":1726611057000},"page":"1408-1411","source":"Crossref","is-referenced-by-count":1,"title":["Pembrolizumab-associated Neuronopathy with Improved Lower Limb Somatosensory Evoked Potential After Intravenous Methylprednisolone Treatment"],"prefix":"10.2169","volume":"64","author":[{"given":"Keisuke","family":"Tachiyama","sequence":"first","affiliation":[{"name":"Department of Clinical Neuroscience and Therapeutics, Hiroshima University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Naito","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience and Therapeutics, Hiroshima University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Nakamori","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience and Therapeutics, Hiroshima University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Aoki","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience and Therapeutics, Hiroshima University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience and Therapeutics, Hiroshima University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Suzuki S, Ishikawa N, Konoeda F, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89: 1127-1134, 2017.","DOI":"10.1212\/WNL.0000000000004359"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Touat M, Maisonobe T, Knauss S, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology 91: e985-e994, 2018.","DOI":"10.1212\/WNL.0000000000006124"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Dubey D, David WS, Amato AA, et al. Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology 93: e1093-e1103, 2019.","DOI":"10.1212\/WNL.0000000000008091"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Cuzzubbo S, Javeri F, Tissier M, et al. Neurological adverse events associated with immune checkpoint inhibitors: a review of the literature. Eur J Cancer 73: 1-8, 2017.","DOI":"10.1016\/j.ejca.2016.12.001"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Dubey D, David WS, Reynolds KL, et al. Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann Neurol 87: 659-669, 2020.","DOI":"10.1002\/ana.25708"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Marini A, Bernardini A, Gigli GL, et al. Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology 96: 754-766, 2021.","DOI":"10.1212\/WNL.0000000000011795"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Okada K, Seki M, Yaguchi H, et al. Polyradiculopathy induced by immune checkpoint inhibitors: a case series and review of the literature. J Neurol 268: 680-688, 2021.","DOI":"10.1007\/s00415-020-10213-x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Sheikh SI, Amato AA. The dorsal root ganglion under attack: the acquired sensory ganglionopathies. Pract Neurol 10: 326-334, 2010.","DOI":"10.1136\/jnnp.2010.230532"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer 7: 306, 2019.","DOI":"10.1186\/s40425-019-0805-8"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Holmstroem RB, Nielsen OH, Jacobsen S, et al. COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis. J Immunother Cancer 10: e005111, 2022.","DOI":"10.1136\/jitc-2022-005111"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Fa'ak F, Buni M, Falohun A, et al. Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events. J Immunother Cancer 11: e006814, 2023.","DOI":"10.1136\/jitc-2023-006814corr1"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Miura T, Sonoo M, Shimizu T. Establishment of standard values for the latency, interval and amplitude parameters of tibial nerve somatosensory evoked potentials (SEPs). Clin Neurophysiol 114: 1367-1378, 2003.","DOI":"10.1016\/S1388-2457(03)00094-4"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/9\/64_4270-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T04:00:58Z","timestamp":1746244858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/9\/64_4270-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":12,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4270-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2025,5,1]]},"article-number":"4270-24"}}